Abstract:BACKGROUND/AIMS:Developing engineered dendritic cell (DC)-targeting lentivectors (LVs) have been the target of intense research for their potential to create antigen-directed immunotherapeutics which can be safely administered to patients. In this study, we constructed a DC-directed LV (LVDC-UbHBcAg-LIGHT) as a potential vaccine to induce anti-HBV immune responses.METHODS:Specificity of LVDC-UbHBcAg-LIGHT for DCs in vivo was confirmed through live animal imaging studies. The levels of cytokine production in T cells were assessed by flow cytometry. The HBcAg-specific cytotoxic T lymphocyte (CTL) responses and antibody responses induced by direct administration of the LVs were detected by LDH release assay and ELISA respectively. The levels of serum HBsAg and HBV DNA were evaluated by Abbott kits and quantitative PCR respectively. The expression levels of HBsAg and HBcAg in liver tissues of HBV transgenic mice were examined by immunohistochemistry. In addition, molecular mechanism underlying the activation of CD8+ T cells was explored.RESULTS:Live animal imaging studies showed that following subcutaneous administration of LVDC-UbHBcAg-LIGHT, no obvious luminescence signal was detected at the injection site. Immunization with LVDC-UbHBcAg-LIGHT elicited potent T cell responses in HBV transgenic mice evidenced by increased percentages of IFN-γ, TNF-α and GzmB producing CD8+ T cells as well as IFN-γ producing CD4+ T cells, improved HBcAg-specific CTL activities and antibody responses. Additionally, vaccination with LVDC-UbHBcAg-LIGHT efficiently reduced serum HBsAg, HBV DNA levels and the expression of HBsAg and HBcAg in liver tissues of HBV transgenic mice. More importantly, autophagy was induced in the activated CD8+ T cells, and the induced autophagy noticeably promoted the proliferation of T cells and decreased the frequencies of apoptotic CD8+ T cells by selectively degrading ubiquitinated apoptosis and cell cycle-associated protein aggregates. Futhermore, we confirmed the interaction between autophagosomes and ubiquitinated aggregates by confocal microscopy and immunoprecipitation analysis.CONCLUSIONS:These results demonstrated that LVDC-UbHBcAg-LIGHT provided a simple method of eliciting effective antiviral immune responses in HBV transgenic mice and might potentially be used as a therapeutic strategy to eradicate HBV with more safety and efficiency. Moreover, our results revealed a direct role of autophagy in promoting the survival and proliferation of activated CD8+ T cells.

Immunization with Lentivector Expressing HBV Ag Markedly Improves the Tumor Microenvironment and Result in Regression of Established Tumors (131.44)

Activation of Endogenous CD4 T Cells Stimulates Favorable Immunologic Changes in the Tumor Milieu and Enhances the Antitumor Effect of Lentivector Immunization (48.15)

ImmunizationAntitumor Efficacy of Lentivector Tumor-Infiltrating T Cells and Enhances the Rescues the Effector Function of Blockade of Programmed Death-1 Pathway

Lentiviral Vector Encoding Ubiquitinated Hepatitis B Core Antigen Induces Potent Cellular Immune Responses and Therapeutic Immunity in HBV Transgenic Mice

Immunoglobulin Fc Fragment Tagging Allows Strong Activation of Endogenous CD4 T Cells to Reshape the Tumor Milieu and Enhance the Antitumor Effect of Lentivector Immunization

Therapeutic vaccination with lentiviral vector in HBV-persistent mice and two inactive HBsAg carriers

Blockade of programmed death-1 pathway rescues the effector function of tumor-infiltrating T cells and enhances the antitumor efficacy of lentivector immunization.

Lentivector expressing HBsAg and immunoglobulin Fc fusion antigen induces potent immune responses and results in seroconversion in HBsAg transgenic mice.

Immunization with Lentiviral Vector‑modified Dendritic Cells Encoding Ubiquitinated Hepatitis B Core Antigen Promotes Th1 Differentiation and Antiviral Immunity by Enhancing P38 MAPK and JNK Activation in HBV Transgenic Mice.

An Engineered DC-Targeting Lentivector Induces Robust T Cell Responses and Inhibits HBV Replication in HBV Transgenic Mice Via Upregulating T Cell Autophagy.

Lentivector Prime and Vaccinia Virus Vector Boost Generate High-Quality Cd8 Memory T Cells and Prevent Autochthonous Mouse Melanoma

Autophagy enhances antitumor immune responses induced by irradiated hepatocellular carcinoma cells engineered to express hepatitis B virus X protein.

Dendritic Cell-Based Vaccination with Lentiviral Vectors Encoding Ubiquitinated Hepatitis B Core Antigen Enhances Hepatitis B Virus-Specific Immune Responses in Vivo

Hepatitis B virus as a gene delivery vector activating foreign antigenic T cell response that abrogates viral expression in mouse models.

Local Delivery of Recombinant Adenovirus Expressing Hepatitis B Virus X Protein and Interleukin-12 Results in Antitumor Effects Via Inhibition of Hepatoma Cell Growth and Intervention of Tumor Microenvironment

In vivo therapeutic effects of affinity-improved-TCR engineered T-cells on HBV-related hepatocellular carcinoma

Vaccination generates functional progenitor tumor-specific CD8 T cells and long-term tumor control

Checkpoint inhibitor-expressing lentiviral vaccine suppresses tumor growth in preclinical cancer models

Correction: Soluble B and T Lymphocyte Attenuator Possesses Antitumor Effects and Facilitates Heat Shock Protein 70 Vaccine-Triggered Antitumor Immunity Against a Murine TC-1 Cervical Cancer Model in Vivo

Local administration of TLR ligands rescues the function of tumor-infiltrating CD8 T cells and enhances the antitumor effect of lentivector immunization.

In Vitro-Activated Tumor-Bearing Host T Cells and the Effectiveness of Tumor Vaccine Immunotherapy